Translational Development of Oral FXIa Inhibitors: A Systematic Review of Molecular Design, Pharmacology, and Indication-Specific Clinical Evidence
Open Access
- 17 August 2026
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1298
Abstract
Background/Objectives: Oral small-molecule inhibitors of activated factor XI (FXIa) are intended to attenuate thrombosis with less disruption of hemostasis than established anticoagulants, but clinical outcomes have not consistently paralleled pharmacodynamic target engagement. This systematic review integrated molecular design, preclinical pharmacology, human pharmacokinetics/pharmacodynamics (PK/PD), and clinical outcomes to identify where translation is maintained or lost. Methods: The review followed PRISMA 2020 and PRISMA-S and was registered in PROSPERO (CRD420261356169). PubMed/MEDLINE, Scopus, and Web of Science Core Collection were searched from inception through 30 March 2026 and rerun on 11 August 2026, with a final publication-eligibility cut-off of 30 June 2026. Owing to heterogeneity, evidence was synthesized narratively. Results: Sixty-eight eligible reports were included, comprising seven randomized parent outcome trials and nine reports with in vivo thrombosis or bleeding experiments. In the OCEANIC-STROKE trial, ischemic stroke occurred in 6.2% with asundexian versus 8.4% with placebo (HR 0.74, 95% CI 0.65–0.84), while major bleeding was 1.9% versus 1.7% (HR 1.10, 95% CI 0.85–1.44). In OCEANIC-AF, stroke or systemic embolism occurred in 1.3% with asundexian versus 0.4% with apixaban (HR 3.79, 95% CI 2.46–5.83), despite less major bleeding (0.2% vs. 0.7%; HR 0.32, 95% CI 0.18–0.55). Conclusions: Oral small-molecule FXIa inhibition is pharmacologically coherent, but clinical benefit is indication-, comparator-, and background-therapy-dependent. PD markers confirm target engagement but are not validated efficacy surrogates; hard clinical outcomes remain decisive.Keywords
This publication has 94 references indexed in Scilit:
- A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy ParticipantsClinical Pharmacology in Drug Development, 2026
- Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular EventsCPT: Pharmacometrics & Systems Pharmacology, 2025
- Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial FibrillationClinical Pharmacology & Therapeutics, 2025
- Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant UseJAMA Cardiology, 2025
- Structure-based design and synthesis of novel FXIa inhibitors targeting the S2' subsite for enhanced antithrombotic efficacyMolecular Diversity, 2024
- No Influence of Asundexian on Cardiac RepolarizationClinical Pharmacology in Drug Development, 2024
- Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in HumansEuropean Journal of Drug Metabolism and Pharmacokinetics, 2023
- The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese VolunteersClinical Drug Investigation, 2023
- Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of AsundexianClinical Pharmacology in Drug Development, 2022
- Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa InhibitorCardiology and Therapy, 2022